2026 LBS.01: The Dr. Eugene Braunwald Late-Breaking Science Session: Translating Science into Prevention: Lessons from Landmark Trials

Saturday, November 07, 2026, 8:30 a.m. to 9:45 a.m.

• ZEUS – Primary Report of the Ziltivekimab Cardiovascular Outcomes Trial (ZEUS) *
• HORIZON – Effect of Pelacarsen on Cardiovascular Outcomes in Patients With Elevated Lipoprotein(a): Primary Results From the Lp(a) HORIZON Trial
• HORIZON Outcomes Extended Analyses of Cardiovascular Outcomes With Pelacarsen Treatment in the Lp(a)Horizon Trial

LBS.02: Late-breaking Science: Treating the Clot or Controlling the Blood Pressure: Improving Outcomes After Stroke

Saturday, November 07, 2026, 1:45 p.m. to 2:45 p.m.

• ADJUVANT – Intravenous Tirofiban versus Thrombolysis Before Endovascular Thrombectomy in Acute Ischemic Stroke: The Adjuvant Randomized Clinical Trial (ADJUVANT) *
• OCEANIC-STROKE – Outcomes in the OCEANIC-STROKE Randomized, Placebo-Controlled Trial: FXIa Inhibition by Asundexian in Participants With Non-Cardioembolic Stroke or Transient Ischemic Attack by Non-Laboratory Framingham Risk Score Category (OCEANIC-STROKE) *
• REDUCE – A Randomized Controlled Trial of Spironolactone-Based Blood Pressure Management After Stroke (REDUCE)
• OPTIMAL-Stroke – Intensive Blood-Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Prior Stroke: The OPTIMAL-Stroke Trial

LBS.03: Late-breaking Science: Hot Topics in CVD Prevention

Saturday, November 07, 2026, 3:15 p.m. to 4:30 p.m.

• STREAM – Discontinuing Statins in Multimorbid Older Adults Without Cardiovascular Disease: A Randomized Non-Inferiority Clinical Trial (STREAM)
• OPTIMAL-DIABETES – Intensive Blood Pressure Control for the Prevention of Major Cardiovascular Events in Patients With Type 2 Diabetes - The OPTIMAL-DIABETES Trial *
• eZ-PAVE – Statin-Ezetimibe Combination Therapy versus Statin Monotherapy in Patients With Atherosclerotic Cardiovascular Disease: Pre-Specified Second Randomization of the Ez-PAVE Trial *
• Yoga-CaRe HF – Yoga-Based Cardiac Rehabilitation in Heart Failure With Reduced Ejection Fraction

LBS.04 Late-breaking Science: Innovations to Optimize Arrhythmia Care

Sunday, November 08, 2026, 3:30 p.m. to 4:45 p.m.

• OptimPacing – Left Bundle Branch Pacing versus Right Ventricular Pacing for Atrioventricular Block: An International Multi-Center Randomized Controlled Trial
• COAST-AF Randomized – Characterization of Arrhythmia Substrate to Ablate Persistent Atrial Fibrillation: COAST-AF Randomized Trial *
• SUPERIOR – Sacubitril/Valsartan for Preventing Recurrence of Atrial Fibrillation After Catheter Ablation in Patients With Hypertension: A Multicenter, Randomized Controlled Trial
• RACE-CARS – Randomized Cluster Evaluation of Cardiac ARrest Systems (RACE-CARS) Trial Primary Results *

LBS.05 Late-breaking Science: New Frontiers in Cardiometabolic Risk Reduction

Monday, November 09, 2026, 8:00 a.m. to 9:15 a.m.

• TYDAL-TIMI 78 – A Randomized Trial of ANGPTL4 Inhibition With MAR001 in Adults With Elevated Triglycerides and Remnant Cholesterol Concentrations
• CTX310– CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3 for Severe Hypertriglyceridemia: Results From Phase 1b Trial
• ATTAIN-OSA – Orforglipron for the Treatment of Obstructive Sleep Apnea: Results From Attain-OSA
• SYNCHRONIZE®-CVOT – Survodutide and Cardiovascular Outcomes in Obesity: Results from the SYNCHRONIZE®-CVOT Tri

LBS.06 Late-breaking Science: Artificial Intelligence in the Diagnosis of Cardiovascular Disease

Monday, November 09, 2026, 9:45 a.m. to 11:00 a.m.

• WATCH-LV – Consumer Smartwatch Artificial Intelligence-Enabled Electrocardiogram for Left Ventricular Systolic Dysfunction: Cross-Manufacturer Validation and Serial Home Monitoring
• PROVAR+ – PROVAR+ External Validation Study
• AI-Assisted Comprehensive Echocardiographic Interpretation—A Blinded, Randomized Controlled Trial
• All-Cause and Cardiovascular Mortality in the U.S.: Risk Stratification via Integrated AI-Enabled Coronary Plaque Analysis and FFR_Ct in Over 269,000 Patients

_{* Accepted but not yet confirmed}

Back to Top

FS.01 – Stable Ischemic Heart Disease: What Happens in the Long Run

Saturday, November 7, 2026, 9:30 a.m. to 10:45 a.m.

• COURAGE – Effect of Percutaneous Coronary Intervention on Long-Term Outcomes in Patients With Stable Ischemic Heart Disease: A 25-Year Follow-Up of the COURAGE Trial
• PARAMOUNT – A Randomized Comparison of Personalized Management for Medical and Interventional Therapy Based on Coronary Atherosclerotic Plaque versus Usual Care for Symptomatic Patients With Suspicion of Coronary Artery Disease: Primary Results of the PARAMOUNT Trial
• ISCHEMIA-EXTEND – Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease
• ISCHEMIA-CKD EXTEND – Long-Term Survival After Initial Invasive or Conservative Management of Stable Coronary Disease in Advanced Chronic Kidney Disease

FS.02 – Death, Drugs, Diagnostics in Thrombosis

Saturday, November 07, 2026, 9:30 a.m. to 10:45 a.m.

• Dynamic Shifts in Cause Specific Mortality After Acute Pulmonary Embolism: A Nationwide Cohort Study *
• ROXI-CATH – Amrecibart and Cenvacibart for the Prevention of Catheter-Related Thrombosis: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
• HI-PRO – Apixaban vs Placebo to Prevent Recurrences in Provoked Venous Thromboembolism With Enduring Risk Factors: One-Year Extension Results From the HI-PRO Trial
• SPEED&PEPS – A 4-Level Clinical Probability-Based Diagnostic Strategy for Suspected Pulmonary Embolism in Emergency Departments: A Cluster-Randomized Trial *

FS.03 Topline Results in Heart Rhythm Care

Saturday, November 07, 2026, 1:30 p.m. to 2:45 p.m.

• EU-CERT-ICD – Clinical Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators: Late Follow-Up Results of the EU-CERT-ICD Controlled Multi Center Cohort Study
• Rethinking Atrial Fibrillation (AF) Burden: AF Density Further Stratifies Heart Failure Risk in a Nationwide Cohort of Patients With Cardiac Devices
• Improved Identification of Near-Term Heart Failure Risk in Pooled Cohort Studies Using ECG-AI and PREVENT-HF
• Subclinical AF and Stroke: Is There a Safe AF Burden?
• First-in-Human Evaluation of Bay 3670549, a Selective GIRK4 Inhibitor for Pharmacological Cardioversion in Patients With Atrial Fibrillation *
• LATENT – Artificial Intelligence-Guided Electrocardiographic Risk Stratification With Targeted Ambulatory Monitoring for Early Detection of Atrial Fibrillation and Pre-Atrial Fibrillation Atrial Findings: The LATENT Randomized Clinical Trial

FS.04 Featured Science in Acute Coronary Syndromes

Saturday, November 07, 2025, 1:30 p.m. to 2:45 p.m.

• VIHP – Two-Week Helicobacter Pylori Eradication versus Six-Month Pantoprazole for Prevention of Gastrointestinal Bleeding After Percutaneous Coronary Intervention for Acute Coronary Syndrome: The VIHP Randomized Trial *
• SWITCH SWEDEHEART – Contemporary Cost-Effectiveness of Default Prasugrel versus Ticagrelor Policies in Acute Coronary Syndromes *
• DAPT-SHOCK-AMI – Multimodality Cardiac Imaging Substudy of the DAPT-SHOCK-AMI Randomized Trial: Echocardiographic and Cardiac Magnetic Resonance Assessment of Cangrelor vs. Crushed Ticagrelor in Cardiogenic Shock Complicating Acute Myocardial Infarction
• PRESC1SE-MI – One-Year Outcomes After Implementation of the 0/1-Hour Pathway: A Prespecified Secondary Analysis of a Randomized Controlled Trial *
• CHIP-BCIS3 – Periprocedural Myocardial Injury, Microaxial Flow Pump Use and Cardiovascular Death After Complex Percutaneous Coronary Intervention: Insights From a Pre-Specified Analysis of the CHIP-BCIS3 Trial

FS.05: Novel Lipid Lowering Therapies

Saturday, November 07, 2026, 3:15 p.m. to 4:30 p.m.

• SRSD216 – A Once Yearly Novel Small Interfering RNA Therapeutic to Lipoprotein(a) Provides Time Averaged Annualized Reduction of 85% After a Single Dose - A Phase 1 Study
• RN0361 – a Novel Quaternary Gal-NAc siRNA, for the Treatment of Hypertriglyceridemia: A Phase 2a, Placebo-Controlled, Single Dose, Parallel Group Study
• First-in-Human Trial of a Dual Functional RNAi Molecule to Silence Expression of Both PCSK9 and APO3 in Mixed Hyperlipidemia
• RESOLVE-1 – Anti-Inflammatory Efficacy and Safety of Oral NLRP3 Inhibitor Ruvonoflast: Results From the Phase 2 RESOLVE-1 Trial
• Triglyceride Lowering and Acute Pancreatitis (AP) Risk Reduction With Plozasiran in Severe Hypertriglyceridemia (sHTG): A Pooled Analysis of SHASTA-3 and SHASTA-4

FS.06 Translating Evidence to Practice: Rigorous Evaluations of Human, Digital and Environmental Intervention

Sunday, November 08, 2026, 9:30 a.m. to 10:45 a.m.

• Lipoprotein(a), Aspirin and Cardiovascular Events in Older Adults
• LINKED-BP – Home Blood Pressure Telemonitoring Linked With Community Health Workers to Improve Blood Pressure: The LINKED-BP Program Cluster-Randomized Controlled Trial
• The Effect of a Community-Based Cardiovascular Health Intervention in Black Men on Life’s Essential 8 and Perceived Stress: Black Impact
• PMHH -The Penn Medicine Healthy Heart Trial: Reducing Clinician Burden for ASCVD Risk Management
• ADHERE-ASCVD – Digital Outreach Modalities to Improve Statin Refill Adherence Across the Age Spectrum: Insights From the ADHERE-ASCVD Randomized Clinical Trial
• Cleaner Air for Lower Cardiometabolic Risk: A Randomized, Double-Blind, Sham-Controlled Trial of Air Pollution Reduction

FS.07 Heart Failure Care for Novel Phenotypes

Sunday, November 08, 2026, 9:30 a.m. to 10:45 a.m.

• IRONMET-HFpEF – Impact of Intravenous Iron Repletion on Mechanisms of Exercise Intolerance in Heart Failure With Preserved Ejection Fraction: The IRONMET-HFpEF Trial Primary Results
• SUMMIT – Tirzepatide and Reverse Remodeling of the Left Atrium and Right Heart in Obesity-Related Heart Failure With Preserved Ejection Fraction
• DAPARHT – Dapagliflozin for Renal Protection in Heart Transplant Recipients
• CADENCE – Effects of Sotatercept on Cardiac Structure and Function: Analysis of the CADENCE Study
• ELPIS II – A Phase 2b Randomized Clinical Trial to Evaluate the Efficacy and Safety of Laromestrocel as Adjunct Therapy During Stage II Palliation for Hypoplastic Left Heart Syndrome
• Semaglutide Ameliorates the Seminal Hemodynamic Features of Obesity-Related HFpEF: A Placebo Controlled Randomized Clinical Trial

FS.08: Old Meds, New Meds and BP Goals: Optimizing Antihypertensive Therapy

Sunday, November 08, 2026, 3:30 p.m. to 4:30 p.m.

• CATCH – Single-Pill Combination Strategy for Hypertension Control in Resource-Constrained Settings: A Cluster-Randomized Trial
• TRANSFORM-HTN – Transform-HTN: Long-Term Efficacy and Safety of Lorundrostat, a Novel Aldosterone Synthase Inhibitor, in Uncontrolled Hypertension
• Angiotensinogen RNA Interference With LDR2402 for Hypertension

FS.09: Featured Science: Lp(a)

Sunday, November 8, 2026, 3:30 p.m. to 4:30 p.m.

• Optimization of Atherogenic Lipid Management With RN5681, a Bivalent SiRNA Targeting PCSK9 and Lp(a)
• FB7023, a Novel Dual-Targeting siRNA Against PCSK9 and Lpa, Simultaneously Reduces Both LDL-C and Lp(a), Exhibiting High-Value Treatment Potential for Management of ASCVD
• Prospective In Silico Prediction of the Lp(a) HORIZON Trial Using a Mechanistic Atherosclerotic Cardiovascular Disease Model
• Frenchie Lpa - Variability of Lipoprotein(a) Measurement Between Acute Myocardial Infarction at Admission, Discharge and Follow Up

FS.10: Digital-Driven Solutions: Connecting the Patient and Provider for HF Transformation

Sunday, November 08, 2026, 3:30 p.m. to 4:30 p.m.

• DETECT-HF - Results of a Prospective, International, Multicenter, Pivotal Validation Study of Remote Voice Analysis for Monitoring Ambulatory Heart Failure Patients
• BETTER CARE-HF – Building Electronic Tools To Enhance and Reinforce CArdiovascular REcommendations for Heart Failure (BETTER CARE-HF) Multi-Center Trial: A Pragmatic Cluster Trial of an Ambulatory Alert Across Multiple Health Systems
• PHARM-HF 2 - Randomized Evaluation of Education and Feedback and Referral Nudges to Increase Heart Failure Medication Optimization Among Primary Care Pharmacists in the Veterans Affairs Healthcare System

FS.11: Silencing ATTR-CM: Lessons from Helios-B and CardioTransform

Monday, November 09, 2026, 9:30 a.m. to 10:45 a.m.

• HELIOS-B - 2-Year Results From the Open-Label Extension Period of the Phase 3 HELIOS-B Study of Vutrisiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy
• HELIOS-B CPET - The Effect of Vutrisiran on Exercise Capacity and Ventilatory Efficiency: Insights From the HELIOS-B CPET and Stress Echocardiography Substudy
• CARDIO-TTRansform - Effects of Eplontersen on Cardiac Structure and Function in Patients With Transthyretin Amyloidosis With Cardiomyopathy - Insights From the CARDIO-TTRansform Trial
• CARDIO-TTRansform CMR - Myocardial Responses to Eplontersen in Transthyretin Amyloid Cardiomyopathy

FS.12: Featured Science Potpourri

Monday, November 09, 2026, 1:30 p.m. to 2:45 p.m.

• VESALIUS-CV – Health Economic Outcomes in the Effect of Evolocumab in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke Randomized Trial
• Lp(a)FRONTIERS EXPANSION – Efficacy and Safety of Pelacarsen in Black/African American and Hispanic Participants With Elevated Lipoprotein(a) and Established Atherosclerotic Cardiovascular Disease
• T2T – Test 2 Treat: A Hybrid Effectiveness-Implementation Trial to Improve LDL-C Testing and Management After Hospitalization for Atherosclerotic Cardiovascular Disease
• TIME-SGLT2 TrialTreating the Metabolic Syndrome With a Sodium-Glucose Cotransporter-2 Inhibitor: A Randomised Controlled Trial
• ECG-AI-First Sequential Screening With NT-proBNP for Heart Failure Risk: The HeartShare/AMP-HF Pooled Cohort Study
• Recover-Autonomic - Results From Primary Analysis of the Coordinated versus Usual Nonpharmacologic Care for Postural Orthostatic Tachycardia Syndrome in Long COVID: A Pooled Analysis From the Recover-Autonomic Platform Trial

FS.13: Practice Informing RCTs

Monday, November 09, 2026, 1:30 p.m. to 2:45 p.m.

• PROGRESS - Transcatheter Aortic Valve Replacement or Clinical Surveillance for Moderate Aortic Stenosis: Primary Results From the Progress Randomized Trial
• MITIGATE - Early Percutaneous Mitral Commissurotomy versus Conventional Management for Asymptomatic Severe Mitral Stenosis: Final Outcomes of the MITIGATE Trial
• PREOP-ECHO - Routine Preoperative Echocardiography Before Intermediate-Risk Noncardiac Surgery: The PREOP-ECHO Randomized Clinical Trial
• Rapid- Water-Flow - Phase 3 Multicenter Trial of Automated Point-of-Care Oxygen-15 Water Positron Emission Tomography Myocardial Perfusion Imaging for the Detection of Coronary Artery Disease: The Rapid- Water-Flow Trial*
• RPA-PMI - Active Surveillance for Perioperative Myocardial Infarction/Injury With Robotic Process Automation: A Double-Blind Randomized Controlled Implementation Trial (RPA-PMI)

HCMS.05: HCMS Late Breaking Oral Abstracts

Friday, November 6, 2026, 2:15 p.m. to 3:15 p.m.

• Long-Term Efficacy and Safety of BHB/HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy: Results From the 52-Week Extension Period
• Effect of Aficamten on Cardiac Structure and Function in Nonobstructive Hypertrophic Cardiomyopathy: The Acacia-HCM CMR Study
• Effect of Aficamten on Patient-Reported Health Status in Non-Obstructive Hypertrophic Cardiomyopathy
• Outcomes of Mavacamten Treatment in Adolescents With Obstructive Hypertrophic Cardiomyopathy at 56 Weeks: The SCOUT-HCM Trial

GL-IMP.01: Reimagining Cardiovascular Care for Scalable Global Impact

Friday, November 6, 2026, 11:30 a.m. - 12:45 p.m.

• A Randomized Trial of Sacubitril/Valsartan versus Enalapril in Chronic Chagas Cardiomyopathy With Reduced Ejection Fraction: Results of the ANSWER-HF Biomarker Subanalysis
• Multicenter Evaluation and Geographic Validation of a Risk-Guided Strategy for Prioritizing Cardiovascular Diagnostic and Specialist Care in Resource-Limited Health Systems
• Digital Health Intervention to Optimize Heart Failure Management After Hospital Discharge in Brazil: A Randomized Clinical Trial (OPT-HF)

GL-IMP.03: From Algorithms to Access: AI-Driven Innovation in Global Cardiovascular Care

Friday, November 6, 2026, 3:00 p.m. - 4:15 p.m.

• Multicenter Implementation of a Competency-Based Echocardiography Delivery Model With AI-Assisted Acquisition and Remote Cardiologist Interpretation

GL-IMP.06: Dyslipidemia as a Global Epidemic: Why Guidelines Must Travel Well

Sunday, November 8, 2026, 3:30 p.m. - 4:45 p.m.

• The Optimal Lipid Marker for Cardiovascular Risk- Findings From Large South Asian CARRS Cohort*

GL-IMP.07: Hypertension and the Cardio-Kidney-Metabolic Axis: From Global Burden to Clinical Impact

Monday, November 9, 2026, 9:45 a.m. - 11:00 a.m.

• Intensive versus Standard Blood-Pressure Control Among 13,844 Patients With Stroke, Transient Ischemic Attack, or Type 2 Diabetes: Main Results of the OPTIMAL-Program
• Accuracy of Community Health Worker-Led Out-of-Office Blood Pressure Measurement in Two Rural Sub-Saharan African Populations (IHCoR (Improving Hypertension Control in Rural Sub-Saharan Africa))*

^* Accepted, not confirmed.

Back to Top

LBBS.AOS.01 – Late-breaking Basic Science: Frontiers in Cardiac Disease Mechanisms and Therapeutic Innovation

Saturday, November 7, 2026, 3:15 p.m. to 4:30 p.m.

• Longitudinal Multimodal Imaging and Proteomics Reveal Mechanisms of Disease Progression in a Mouse Model of Transthyretin Amyloid Cardiomyopathy*
• Lx2021, an AAV-Based Gene Therapy Improves Cardiomyopathy Phenotype and Lifespan in a Severe Desmoplakin Cardiomyopathy Mouse Model
• Glutamine-Fructose-6-Phosphate Transaminase 2 Drives Pressure Overload-Induced Cardiac Fibrosis Through O-Linked N-Acetylglucosamine Modification of Heat Shock Protein 47*
• A Novel, Reproducible, Optogenetically Controlled Cardiac Tissue-Engineering Platform Accurately Recapitulates Clinical Drug Responses for Drug Development and Discovery*
• Fluorescent Bead Microangiography Reveals Pulmonary Venous Remodeling in Experimental Pulmonary Hypertension and Heart Failure With a Preserved Ejection Fraction

LBBS.AOS.02 – Late-breaking Models and Mechanisms in Atherosclerosis and Calcific Aortic Valve Disease

Sunday, November 8, 2026, 9:45 – 11:00 AM

• Inflammatory Chromatin Remodeling in Circulating Monocytes Precedes Progression to Myocardial Infarction
• KAT2A Mediates ALDOA Malonylation to Promote Calcific Aortic Valve Disease Through Metabolic Reprogramming of Valvular Interstitial Cells
• Alcohol Dehydrogenase 5 Sumoylation Regulates Macrophage Autophagy in Homocysteine-Induced Atherosclerosis*
• Ubiquitination-Autophagy Crosstalk Orchestrates Oxidative Stress-Induced Senescence to Promote Calcific Aortic Valve Disease
• A Living Human Coronary Artery With Plaque Model for Functional and Pharmacologic Study of Coronary Disease*

LBBS.MDP.01- Mechanisms of Cardiac Remodeling: From Molecules to Therapeutics

Saturday, November 7, 2026, 9:15 – 10:30 AM

• Cationic Proteins From Eosinophils Engages Distinct BMP Receptors in Cardiomyocytes and Cardiac Fibroblasts to Protect Against Pressure Overload-Induced Cardiac Remodeling
• One-Shot Remote Self-Amplifying RNA Therapy Enables Durable Cardioprotection
• Empagliflozin Drives Rapid Recovery of Diastolic Function and Rescue of Stalled Flow in Coronary Capillaries After One Day in the Two-Hit Mouse Model of HFpEF
• Untranslated Regions Spatially Organize Atp2a2 Messenger RNA via Microtubules in Adult Cardiomyocytes*

LBBS.MDP.01- Mechanisms of Cardiac Remodeling: From Molecules to Therapeutics

Saturday, November 7, 2026, 9:15 – 10:30 AM

• Cationic Proteins From Eosinophils Engages Distinct BMP Receptors in Cardiomyocytes and Cardiac Fibroblasts to Protect Against Pressure Overload-Induced Cardiac Remodeling
• One-Shot Remote Self-Amplifying RNA Therapy Enables Durable Cardioprotection
• Empagliflozin Drives Rapid Recovery of Diastolic Function and Rescue of Stalled Flow in Coronary Capillaries After One Day in the Two-Hit Mouse Model of HFpEF
• Untranslated Regions Spatially Organize Atp2a2 Messenger RNA via Microtubules in Adult Cardiomyocytes*
• Glycosaminoglycan-Peptide Conjugates Targeting Endothelial Adhesion Molecules as a Therapeutic Strategy for Vaso-Occlusion
• Adenine Drives Heart Failure in Type 1 Diabetes Through C-jun-Mediated Mic60 Suppression*
• Collagen Architecture Rather Than Abundance Determines Whether Cardiac Matrix Supports Pacemaking
• Genetic Architecture and Developmental Vascular Features of Congenital Portosystemic Shunt
• Transcriptomic Profiling Indentifies Fibrolink, a Novel Mechanically-Controlled Long Non-Coding RNA Involved in Fibrotic Priming of Human Cardiac Fibroblasts
• Re-Endothelializing HFpEF: Endothelial Replenishment Reverses the Disease Phenotype, Establishes Endothelial Dysfunction as a Causal Driver, and Enables AI-Guided Therapeutic Discovery*

LBBS.MDP.02- Late-Breaking Abstracts in Atherosclerosis, Thrombosis, and Vascular Biology

Saturday, November 7, 2026, 10:45 AM- 12:00 PM

• Differentiated Pharmacologic Profile of ACL-508 in Cholesteryl Ester Transfer Protein-Expressing Preclinical Models*
• Childhood Sexual Abuse and Risk of Myocardial Infarction Among US Adults
• Repurposing Daprodustat for the Treatment of Deep Vein Thrombosis
• Tirzepatide Attenuates Calcific Aortic Valve Disease Through Macrophage Histone Desuccinylation*
• Plasma Lipid Remodeling Links Residual Cardiometabolic Risk to Coronary Atherosclerotic Burden*
• Two-Photon Intravital Imaging of Endothelial cGAS-Mediated Vascular Injury and Pathologic Immune Traffic in Sepsis*
• A Pleiotropic Pan-Effective Drug Targeting APOB and DGAT2 for Cardiometabolic Disease
• PRDM16 Alters Coronary Artery Disease Risk by Epigenetically Regulating Smooth Muscle Cell Phenotypic Modulation Through Two Mechanisms*
• STX-1150 Provides Persistent LDL-C Control for at Least Two Years After a Single Dose, a Novel Epigenetic Silencing Approach
• Loss of CD38 Expression Protects Against Age-Associated Hypertension and Endothelial Dysfunction*

LBBS.APBS.01- Abstract Poster Board Session (Flat boards) - Late-breaking Basic Science Abstracts

Saturday, November 7, 2026 2:30- 3:30 PM

• Gut Microbiota Mediates Hypertriglyceridemia and Hepatic Steatosis Induced by Inhalation of Ultrafine Particulate Matter*
• Durable RNAi Silencing of Factor XI by BW-41012 in Humanized Mice and Cynomolgus Monkeys*
• Genetic and Pharmacologic Inhibition of 12‑Lipoxygenase Attenuates Inflammatory‑Metabolic HFpEF*
• Augmented Spinal Drain for Continuous Detection of Spinal Cord Ischemia in a Porcine Aortic Occlusion Model*
• Single-Nuclei Multiomic Profiling of Patient Vascular Tissue Identifies Endothelial Cells as the Predominant Pathogenic Population in Vascular Ehlers-Danlos Syndrome*
• Bioengineered Lung Matrix Programs Capillary Specialization in Human Organoids*
• Estrogen Intervention and Cardiomyocyte Function: A Model for Women's Heart Disease*
• Lipid-Induced 2-Hydroxyglutarate Suppresses Ten-Eleven Translocation DNA Demethylases to Drive Macrophage Inflammation
• Micro and Nanoplastics Promote Atherosclerosis and Exhibit Particle-Specific Atherogenic Effects*
• Novel Human-Induced Pluripotent Stem Cell-Derived Cardiac Myocytes Luciferase Reporter System for Elucidation of Ubiquitin-Proteasome and Neddylation Involvement in ∆R4-23/∆C Micro-Dystrophin Degradation*
• Quantitative Histologic Characterization Reveals a Spectrum of Thrombus Organization in Pulmonary Embolism*
• The Role of Fragile X Mental Retardation Protein in Macrophage Senescence and Atherosclerosis*
• Timed Inhibition of Transient Receptor Potential Canonical Type 6 for the Rescue of Myocardial Infarction*
• Reverse Remodeling Cardiac Physiology in the Maternal Heart: A Role for Mitochondria
• Gene Editing in Human Cardiomyocytes Using Focused Ultrasound*
• Therapeutic Strategies to Circumvent Arrhythmogenic Cardiomyopathy
• Effect of Clazakizumab on Free IL-6 in Patients Receiving Maintenance Hemodialysis: A Secondary Analysis of the POSIBIL₆ESKD Phase 2b Trial
• Novel Renal-Protective Mechanism of Empagliflozin: Ciliary Control of Proximal Tubular Lipid Droplet Accumulation*
• SGK1 Inhibition, Monotherapy or in Combination With Incretin Agonism, Targets Residual Risk in Cardiometabolic Heart Failure
• A Compact Bidirectional Cardiomyocyte-Specific Promoter Driving Co-Expression of HCN4t and ADRB2 Delivers Adrenergic Responsive Biological Pacing
• Molecular Imaging of the Inflammatory-Fibrotic Response in Transthyretin Amyloid Cardiomyopathy
• RESOLVE-AF De Novo Cohort One-Year Outcomes*
• The Migration of Macrophages and Their Interaction With Epicardial Precursors Contribute to Atrial Cardiomyopathy Associated With Obesity
• Stress Induced Rna Decay in Cardiac Hypertrophy
• Semaglutide Mitigates Left Atrial and Mitochondrial Dysfunction in a Multi-Hit Aged Female Mouse Model of Heart Failure With Preserved Ejection Fraction
• Targeting Tissue Specific Fibrotic Processes via Preferential Platelet Derived Growth Factor Receptor Subtype Usage
• Ascending Thoracic Aortic Aneurysm is Associated With Alterations in the Circulating Cytotoxic T-Lymphocyte Transcriptome in Patients With and Without Bicuspid Aortic Valve*
• Pathogenic Junctophilin-2 Variants Disrupt Cardiac Sarcoplasmic Reticulum-Mitochondrial Coupling and Fatty Acid Oxidation*
• Targeting ClpP-Mediated Mitochondrial Proteostasis Reduces Vascular Senescence and Atherosclerosis*

^* Accepted, not confirmed.

Back to Top